Repligen (RGEN) 10-Q 8 May 18 2018 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2018	May 01, 2018
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q1
Trading Symbol	RGEN
Entity Registrant Name	REPLIGEN CORP
Entity Central Index Key	730,272
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		43,693,913

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 173,876	$ 173,759
Accounts receivable, less reserve for doubtful accounts of $59 at March 31, 2018 and $58 at December 31, 2017, respectively	29,352	27,585
Royalties and other receivables	31	153
Inventories, net	40,124	39,004
Prepaid expenses and other current assets	4,939	2,281
Total current assets	248,322	242,782
Property, plant and equipment, net	22,674	22,417
Intangible assets, net	142,273	144,753
Goodwill	327,989	327,333
Other assets	1,990	6,234
Total assets	743,248	743,519
Current liabilities:
Accounts payable	6,200	7,282
Accrued liabilities	14,121	17,929
Total current liabilities	20,321	25,211
Convertible senior notes, net	100,276	99,250
Deferred tax liabilities	20,858	25,167
Other long-term liabilities	4,610	2,343
Commitments and contingencies (Note 14)
Stockholders' equity:
Preferred stock, $.01 par value, 5,000,000 shares authorized, no shares issued or outstanding
Common stock, $.01 par value, 80,000,000 shares authorized, 43,692,303 shares at March 31, 2018 and 43,587,079 shares at December 31, 2017 issued and outstanding	437	436
Additional paid-in capital	631,595	628,983
Accumulated other comprehensive loss	(6,112)	(6,363)
Accumulated deficit	(28,737)	(31,508)
Total stockholders' equity	597,183	591,548
Total liabilities and stockholders' equity	$ 743,248	$ 743,519

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Accounts receivable, reserve for doubtful accounts	$ 59	$ 58
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	80,000,000	80,000,000
Common stock, shares issued	43,692,303	43,587,079
Common stock, shares outstanding	43,692,303	43,587,079

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Revenue:
Product revenue	$ 44,799	$ 30,569
Royalty and other revenue	31	21
Total revenue	44,830	30,590
Operating expenses:
Cost of product revenue	19,668	13,990
Research and development	3,288	1,742
Selling, general and administrative	15,898	9,182
Total operating expenses	38,854	24,914
Income from operations	5,976	5,676
Investment income	181	96
Interest expense	(1,652)	(1,585)
Other income (expense)	71	(120)
Income before income taxes	4,576	4,067
Income tax provision	1,128	999
Net income	$ 3,448	$ 3,068
Earnings per share:
Basic	$ 0.08	$ 0.09
Diluted	$ 0.08	$ 0.09
Weighted average shares outstanding:
Basic	43,621,270	33,891,702
Diluted	44,326,732	34,382,322
Other comprehensive income:
Unrealized gain on investments		$ 4
Foreign currency translation gain	$ 251	1,027
Comprehensive income	$ 3,699	$ 4,099

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Cash flows from operating activities:
Net income	$ 3,448	$ 3,068
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	3,960	1,582
Non-cash interest expense	1,036	970
Stock-based compensation expense	2,268	1,531
Deferred tax expense	449	10
Loss on conversion of senior convertible notes	1
Loss on disposal of assets		59
Changes in assets and liabilities:
Accounts receivable	(1,529)	(2,415)
Other receivables	127	172
Inventories	(1,188)	851
Prepaid expenses and other current assets	(1,608)	34
Accounts payable	(1,550)	(452)
Accrued liabilities	(3,839)	(4,220)
Long-term liabilities	(3)	(43)
Net cash provided by operating activities	1,572	1,147
Cash flows from investing activities:
Purchases of marketable securities		(28)
Redemptions of marketable securities		7,400
Purchases of property, plant and equipment	(1,564)	(1,295)
Net cash (used in) provided by investing activities	(1,564)	6,077
Cash flows from financing activities:
Exercise of stock options	344	1,333
Repayment of senior convertible notes	(11)
Payment of contingent consideration		(1,663)
Net cash provided by (used in) financing activities	333	(330)
Effect of exchange rate changes on cash and cash equivalents	(224)	536
Net increase (decrease) in cash and cash equivalents	117	7,430
Cash, cash equivalents and restricted cash, beginning of period	173,759	122,683
Cash, cash equivalents and restricted cash, end of period	173,876	130,113
Supplemental disclosure of non-cash activities:
Income taxes paid	937	1,181
Non-cash effect of adoption of ASU 2016-16	$ 5,609
Payment of contingent consideration in common stock		$ 1,062

Basis of Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2018
Basis of Presentation	1. Basis of Presentation The condensed consolidated financial statements included herein have been prepared by Repligen Corporation (the “Company,” “Repligen” or “we”) in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”), for Quarterly Reports on Form 10-Q S-X 10-K The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Repligen Sweden AB (“Repligen Sweden”), Repligen GmbH, Repligen Singapore Pte. Ltd., our former subsidiary, TangenX Technology Corporation (“TangenX,” acquired on December 14, 2016 and merged into the Company as of June 30, 2017) and Spectrum LifeSciences, LLC (“Spectrum,” acquired on August 1, 2017). All significant intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of only normal, recurring adjustments necessary for a fair presentation of the financial position, results of operations and cash flows. The results of operations for the interim periods presented are not necessarily indicative of results to be expected for the entire year. Recently Issued Accounting Pronouncements In May 2014, the FASB issued ASU No. 2014-09, Revenue Recognition Revenue from Contracts with Customers 2015-14, 2016-08, 2016-10, 2016-12, In January 2016, the FASB issued ASU No. 2016-01, 825-10): In February 2016, the FASB issued ASU No. 2016-02, “Leases 2016-02”). 2016-02 right-of-use In August 2016, the FASB issued ASU No. 2016-15, No. 2016-15 In October 2016, the FASB issued ASU 2016-16, “Intra-Entity 2016-16 In November 2016, the FASB issued ASU No. 2016-18, In January 2017, the FASB issued ASU No. 2017-01, “Business 2017-01 In January 2017, the FASB issued ASU No. 2017-04, No. 2017-04

Acquisition of Spectrum LifeSci

Acquisition of Spectrum LifeSciences, LLC	3 Months Ended
	Mar. 31, 2018
Acquisition of Spectrum LifeSciences, LLC	2. Acquisition of Spectrum LifeSciences, LLC On August 1, 2017, the Company completed the acquisition of Spectrum pursuant to the terms of an Agreement and Plan of Merger and Reorganization, dated as of June 22, 2017 (such acquisition, the “Spectrum Acquisition”). Spectrum is a diversified filtration company with a differentiated portfolio of hollow fiber cartridges, bench-top single-use Spectrum’s filtration products include its KrosFlo ® single-use ® Pro-Connex ® single-use Module-Bag-Tubing ® Consideration Transferred The Company accounted for the Spectrum Acquisition as a purchase of a business under ASC 805, “Business Combinations.” The Spectrum Acquisition was funded through payment of approximately $122.9 million in cash, 6,153,995 unregistered shares of the Company’s common stock totaling $247.6 million and a working capital adjustment of $425,000 for a total purchase price of $370.9 million. Under the acquisition method of accounting, the assets of Spectrum were recorded as of the acquisition date, at their respective fair values, and consolidated with those of the Company. The fair value of the net assets acquired was approximately $370.9 million. The estimated consideration and preliminary purchase price information has been prepared using a valuation that required the use of significant assumptions and estimates in its preparation. Critical estimates included, but were not limited to, future expected cash flows, including projected revenues and expenses, and the applicable discount rates. These estimates were based on assumptions that the Company believes to be reasonable; however, actual results may differ from these estimates. The total consideration transferred follows (in thousands): Cash consideration $ 122,932 Equity consideration 247,575 Working capital adjustment 425 Net assets acquired $ 370,932 Acquisition-related costs are not included as a component of consideration transferred, but are expensed in the periods in which the costs are incurred. The Company has incurred $655,000 in costs related to the Spectrum Acquisition for the three-month period ended March 31, 2018 and $7,060,000 in costs for the year ended December 31, 2017. These costs are primarily included in selling, general and administrative expenses in the consolidated statements of operations. Fair Value of Net Assets Acquired The allocation of purchase price was based on the fair value of assets acquired and liabilities assumed as of August 1, 2017, based on the preliminary valuation. The components and allocation of the purchase price consists of the following amounts (in thousands): Cash and cash equivalents $ 10,137 Accounts receivable 5,075 Inventory 13,570 Prepaid expenses and other assets 616 Fixed assets 6,004 Deferred tax assets 1,102 Customer relationships 78,400 Developed technology 38,560 Trademark and tradename 2,160 Non-competition agreements 960 Goodwill 265,654 Accounts payable (1,335 ) Unrecognized tax benefit (576 ) Accrued liabilities (5,787 ) Deferred tax liabilities (43,608 ) Fair value of net assets acquired $ 370,932 Of the consideration paid, $78.4 million represents the fair value of customer relationships that is amortized over the weighted average determined useful life of 15 years, and $38.6 million represents the fair value of developed technology that is amortized over a determined useful life of 20 years. $960,000 represents the fair value of non-competition The goodwill of $265.7 million represents future economic benefits expected to arise from synergies from combining operations and commercial organizations to increase market presence and the extension of existing customer relationships. None of the goodwill recorded is expected to be deductible for income tax purposes. The purchase price allocation may be subject to adjustment as purchase accounting is preliminary as of March 31, 2018 related to inventory valuation. The final allocation may include, but not be limited to, changes in allocations to inventory and goodwill. Revenue, Net Income and Pro Forma Presentation The Company recorded revenue from Spectrum of $11,719,000 for the three-month period ended March 31, 2018. The Company has included the operating results of Spectrum in its consolidated statements of operations since the August 1, 2017 acquisition date. The following table presents unaudited supplemental pro forma information as if the Spectrum Acquisition had occurred as of January 1, 2017 (in thousands, except per share data): Pro-forma Three months ended March 31, 2018 Pro-forma Three months ended March 31, 2017 Total revenue 44,830 39,875 Net income 3,939 3,266 Earnings per share: Basic $ 0.09 $ 0.08 Diluted $ 0.09 $ 0.08 The unaudited pro forma information for the three-month period ended March 31, 2018 was calculated after applying the Company’s accounting policies and the impact of acquisition date fair value adjustments. The unaudited pro forma net income for the three-month period ended March 31, 2018 was adjusted to exclude acquisition-related transaction costs, as these expenses would have been incurred in the prior year assuming the Spectrum Acquisition closed on January 1, 2017. These pro forma condensed consolidated financial results include certain adjustments to reflect the pro forma results of operations as if the acquisition had occurred as of January 1, 2017. The pro forma information does not reflect the effect of costs or synergies that would have been expected to result from the integration of the acquisition. The pro forma information does not purport to be indicative of the results of operations that actually would have resulted had the combinations occurred at the beginning of the period presented, or of future results of the consolidated entities.

Revenue Recognition

Revenue Recognition	3 Months Ended
	Mar. 31, 2018
Revenue Recognition	3. Revenue Recognition Adoption of ASC Topic 606, Revenue from Contracts with Customers The Company adopted ASC 606 on January 1, 2018, using the modified retrospective method for all contracts not completed as of the date of adoption. For contracts that were modified before the effective date, the Company reflected the aggregate effect of all modifications when identifying performance obligations and allocating transaction price in accordance with the practical expedient in paragraph ASC 606-10-65-1-(f)-4, Revenue Recognition Revenue is recognized when, or as, obligations under the terms of a contract are satisfied, which occurs when control of the promised products or services is transferred to customers. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products or services to a customer (“transaction price”). To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method or the most likely amount method, depending on the facts and circumstances relative to the contract. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of the Company’s anticipated performance and all information (historical, current and forecasted) that is reasonably available. Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue. When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Applying the practical expedient in paragraph 606-10-32-18, Contracts with customers may contain multiple performance obligations. For such arrangements, the transaction price is allocated to each performance obligation based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations. The Company recognizes product revenue under the terms of each customer agreement upon transfer of control to the customer, which occurs at a point in time. Disaggregation of Revenue Revenues for the three-month periods ended March 31, 2018 and 2017 were as follows: Three months ended March 31, (in thousands, except percentages) 2018 2017 $ Change % Change Product revenue $ 44,799 $ 30,569 $ 14,230 47 % Royalty and other revenue 31 21 10 48 % Total revenue $ 44,830 $ 30,590 $ 14,240 47 % When disaggregating revenue, the Company considered all of the economic factors that may affect its revenues. Because all of its revenues are from bioprocessing customers, there are no differences in the nature, timing and uncertainty of the Company’s revenues and cash flows from any of its product lines. However, given that the Company’s revenues are generated in different geographic regions, factors such as regulatory and geopolitical factors within those regions could impact the nature, timing and uncertainty of the Company’s revenues and cash flows. In addition, a significant portion of the Company’s revenues are generated from two customers; therefore, economic factors specific to these two customers could impact the nature, timing and uncertainty of the Company’s revenues and cash flows. The following tables disaggregate the Company’s revenue from contracts with customers by geographic region (in thousands). Three months ended North America $ 20,239 Europe 19,401 Asia and Pacific 4,947 Other 243 Total revenue $ 44,830 Revenue from significant customers is as follows (in thousands): Three months ended GE Healthcare $ 7,717 MilliporeSigma $ 6,465 Protein Products The Company’s protein product line generates revenue through the sale of Protein A ligands, an essential component of Protein A chromatography resins (media) used in the purification of virtually all mAb-based Filtration Products The Company’s filtration product line generates revenue through the sale of KrosFlo ® ® single-use The Company markets the KrosFlo line of HF cartridges and TFF systems and the ProConnex line of single-use flow path connectors which were acquired as part of the acquisition of Spectrum in August 2017. These products are used in the filtration, isolation, purification and concentration of biologics and diagnostic products. Sales of large-scale systems generally include components and consumables as well as training and installation services at the request of the customer. Because the initial sale of components and consumables are necessary for the operation of the system, such items are combined with the systems as a single performance obligation. Training and installation services do not significantly modify or customize these systems and therefore represent a distinct performance obligation. Each of the Company’s other product offerings are not highly interdependent of one another and are therefore considered distinct products that represent separate performance obligations. Revenue on these products is generally recognized at a point in time upon transfer of control to the customer. The Company invoices the customer for the installation and training services in an amount that directly corresponds with the value to the customer of the Company’s performance to date; therefore, revenue recognized is based on the amount billable to the customer in accordance with the practical expedient under ASC 606-10-55-18. The Company also markets flat sheet TFF cassettes and hardware, which were acquired as part of the acquisition of TangenX Technology in December 2016. TFF is a rapid and efficient method for separation and purification of biomolecules that is widely used in laboratory, process development and process scale applications in biopharmaceutical manufacturing. The Company’s single-use The Company also markets the XCell™ ATF System, a technologically advanced filtration device used in upstream processes to continuously remove cellular metabolic waste products during the course of a fermentation run, freeing healthy cells to continue producing the biologic drug of interest. ATF Systems typically include a filtration system and consumables (i.e., tube devices, metal stands) as well as training and installation services at the request of the customer. The filtration system and consumables are considered distinct products and therefore represent separate performance obligations. First time purchasers of the systems typically purchase a controller that is shipped with the tube device(s) and metal stand(s). The controller is not considered distinct as it is a proprietary product that is highly interdependent with the filtration system; therefore, the controller is combined with the filtration system and accounted for as a single performance obligation. The training and installation services do not significantly modify or customize the ATF system and therefore represent a distinct performance obligation. ATF system product revenue related to the filtration system (including the controller if applicable) and consumables is generally recognized at a point in time upon transfer of control to the customer. ATF system service revenue related to training and installation services is generally recognized over time, as the customer simultaneously receives and consumes the benefits as the Company performs. The Company invoices the customer for the installation and training services in an amount that directly corresponds with the value to the customer of the Company’s performance to date; therefore, revenue recognized is based on the amount billable to the customer in accordance with the practical expedient under ASC 606-10-55-18. Chromatography Products The Company’s chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs. The majority of chromatography revenue relates to the OPUS pre-packed Other Products The Company’s other products include ELISA test kits used by quality control departments to detect and measure the presence of leached Protein A and/or growth factor in the final product. Each ELISA kit is considered distinct and therefore represents a separate performance obligation. Other product revenue is generally recognized at a point in time upon transfer of control to the customer. Transaction Price Allocated to Future Performance Obligations Remaining performance obligations represents the transaction price of contracts for which work has not been performed or has been partially performed. The Company’s future performance obligations relate primarily to the installation and training of certain of its systems sold to customers. These performance obligations are completed within one year of receipt of a purchase order from its customers. Accordingly, the Company has elected to not disclose the value of these unsatisfied performance obligations as provided under ASC 606-10-50-14. Contract Balances from Contracts with Customers The following table provides information about receivables and deferred revenue from contracts with customers as of March 31, 2018: 2018 Balances from contracts with customers only: Accounts receivable $ 29,352 Deferred revenue 1,547 Revenue recognized in the period relating to: The beginning deferred revenue balance $ 434 Changes in pricing related to products or services satisfied in previous periods — Impairment losses on receivables — The timing of revenue recognition, billings and cash collections results in accounts receivables and deferred revenue on the Company’s consolidated balance sheets. A contract asset is created when the Company satisfies a performance obligation by transferring a promised good to the customer. Contract assets may represent conditional or unconditional rights to consideration. The right is conditional, and recorded as a contract asset, if the Company must first satisfy another performance obligation in the contract before it is entitled to payment from the customer. Contract assets are transferred to billed receivables once the right becomes unconditional. If the Company has the unconditional right to receive consideration from the customer, the contract asset is accounted for as a billed receivable and presented separately from other contract assets. A right is unconditional if nothing other than the passage of time is required before payment of that consideration is due. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded. Contract liabilities are recognized as revenue after control of the products or services is transferred to the customer and all revenue recognition criteria have been met. Costs to Obtain or Fulfill a Customer Contract The Company’s sales commission structure is based on achieving revenue targets. The commissions are driven by revenue derived from customer purchase orders which are short term in nature. Applying the practical expedient in paragraph 340-40-25-4,

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income	3 Months Ended
	Mar. 31, 2018
Accumulated Other Comprehensive Income	4. Accumulated Other Comprehensive Income The following table summarizes the changes in accumulated other comprehensive income by component (in thousands): (In thousands) Foreign currency translation gain (loss) Balance at December 31, 2017 $ (6,363 ) Foreign currency translation gain 251 Balance at March 31, 2018 $ (6,112 )

Earnings Per Share

Earnings Per Share	3 Months Ended
	Mar. 31, 2018
Earnings Per Share	5. Earnings Per Share The Company reports earnings per share in accordance with ASC Topic 260, “Earnings Per Share,” which establishes standards for computing and presenting earnings per share. Basic earnings per share is computed by dividing net income available to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing net income available to common shareholders by the weighted-average number of common shares and dilutive common share equivalents then outstanding. Potential common share equivalents consist of restricted stock awards and the incremental common shares issuable upon the exercise of stock options. Under the treasury stock method, unexercised “in-the-money” non-forfeitable Basic and diluted weighted average shares outstanding were as follows: Three months ended March 31, 2018 2017 Basic weighted average common shares outstanding 43,621,270 33,891,702 Effect of dilutive securities: Stock options and restricted stock awards 389,702 490,620 Convertible senior notes 315,760 — Weighted average common shares, assuming dilution 44,326,732 34,382,322 At March 31, 2018, there were outstanding options to purchase 1,109,353 shares of the Company’s common stock at a weighted average exercise price of $25.34 per share and 703,076 restricted stock units. For the three months ended March 31, 2018, 593,874 options to purchase shares of the Company’s common stock were excluded from the calculation of diluted earnings per share because the exercise prices of the stock options were greater than or equal to the average price of the common shares, and were therefore anti-dilutive. At March 31, 2017, there were outstanding options to purchase 805,903 shares of the Company’s common stock at a weighted average exercise price of $19.68 per share and 404,781 restricted stock units. For the three months ended March 31, 2017, 458,685 options to purchase shares of the Company’s common stock were excluded from the calculation of diluted earnings per share because the exercise prices of the stock options were greater than or equal to the average price of the common shares, and were therefore anti-dilutive. As provided by the terms of the indenture underlying the Company’s 2.125% Convertible Senior Notes due 2021 (the “Notes”), the Company has a choice to settle the conversion obligation for the Notes in cash, shares or any combination of the two. The Company currently intends to settle the par value of the Notes in cash and any excess conversion premium in shares. The Company applies the provisions of ASC 260, Earnings Per Share, 10-45-44,

Inventories

Inventories	3 Months Ended
	Mar. 31, 2018
Inventories	6. Inventories Inventories relate to the Company’s bioprocessing business. The Company values inventory at cost or, if lower, market value, using the first-in, first-out work-in-process A change in the estimated timing or amount of demand for the Company’s products could result in additional provisions for excess inventory quantities on hand. Any significant unanticipated changes in demand or unexpected quality failures could have a significant impact on the value of inventory and reported operating results. During all periods presented in the accompanying financial statements, there have been no material adjustments related to a revised estimate of inventory valuations. Work-in-process March 31, 2018 December 31, 2017 Raw Materials $ 21,826 $ 22,351 Work-in-process 3,828 4,083 Finished products 14,470 12,570 Total $ 40,124 $ 39,004

Property, Plant and Equipment

Property, Plant and Equipment	3 Months Ended
	Mar. 31, 2018
Property, Plant and Equipment	7. Property, Plant and Equipment Property, plant and equipment consist of the following (in thousands): March 31, 2018 December 31, 2017 Land $ 1,023 $ 1,023 Buildings 764 764 Leasehold improvements 15,740 15,673 Equipment 22,497 21,904 Furniture and fixtures 4,605 4,272 Construction in progress 3,052 2,581 Total property, plant and equipment 47,681 46,217 Less: accumulated depreciation (25,007 ) (23,800 ) Property, plant and equipment, net $ 22,674 $ 22,417 Depreciation expense totaled approximately $1,284,000 and $928,000 for the three-month periods ended March 31, 2018 and 2017, respectively.

Intangible Assets

Intangible Assets	3 Months Ended
	Mar. 31, 2018
Intangible Assets	8. Intangible Assets Intangible assets are amortized over their useful lives using the straight-line method, as applicable, and the amortization expense is recorded within selling, general and administrative expense in the Company’s statements of comprehensive income. The Company reviews its indefinite-lived intangible assets not subject to amortization to determine if adverse conditions exist or a change in circumstances exists that would indicate an impairment. Intangible assets and their related useful lives are reviewed at least annually to determine if any adverse conditions exist that would indicate the carrying value of these assets may not be recoverable. More frequent impairment assessments are conducted if certain conditions exist, including a change in the competitive landscape, any internal decisions to pursue new or different technology strategies, a loss of a significant customer, or a significant change in the marketplace, including changes in the prices paid for our products or changes in the size of the market for our products. An impairment results if the carrying value of the asset exceeds the estimated fair value of the asset. If the estimate of an intangible asset’s remaining useful life is changed, the remaining carrying amount of the intangible asset is amortized prospectively over the revised remaining useful life. The Company continues to believe that its intangible assets are recoverable at March 31, 2018. Intangible assets consisted of the following at March 31, 2018 (in thousands): Gross Carrying Amount Accumulated Amortization Weighted Average Useful Life (in years) Technology – developed $ 51,860 $ (3,898 ) 19 Patents 240 (240 ) 8 Customer relationships 102,210 (11,446 ) 14 Trademark – definite lived 2,160 (75 ) 20 Trademark – indefinite lived 700 — — Other intangibles 1,066 (304 ) 3 Total intangible assets $ 158,236 $ (15,963 ) 16 Intangible assets consisted of the following at December 31, 2017 (in thousands): Gross Carrying Amount Accumulated Amortization Weighted Average Useful Life (in years) Technology – developed $ 51,801 $ (3,201 ) 19 Patents 240 (238 ) 8 Customer relationships 102,120 (9,636 ) 14 Trademarks – definite lived 2,160 (47 ) 20 Trademarks – indefinite lived 700 — — Other intangibles 1,063 (209 ) 3 Total intangible assets $ 158,084 $ (13,331 ) 16 Amortization expense for amortized intangible assets was approximately $2,664,000 and $715,000 for the three-month periods ended March 31, 2018 and 2017, respectively. As of March 31, 2018, the Company expects to record amortization expense as follows (in thousands): Years Ending Amortization Expense December 31, 2018 (nine months remaining) $ 7,978 December 31, 2019 10,513 December 31, 2020 9,910 December 31, 2021 9,395 December 31, 2022 9,395

Accrued Liabilities

Accrued Liabilities	3 Months Ended
	Mar. 31, 2018
Accrued Liabilities	9. Accrued Liabilities Accrued liabilities consist of the following (in thousands): March 31, 2018 December 31, 2017 Employee compensation $ 5,246 $ 9,560 Taxes 2,049 1,668 Royalty and license fees 1,243 1,383 Accrued purchases 521 1,191 Professional fees 827 947 Unearned revenue 1,547 960 Other accrued expenses 2,688 2,220 Total $ 14,121 $ 17,929

Convertible Senior Notes

Convertible Senior Notes	3 Months Ended
	Mar. 31, 2018
Convertible Senior Notes	10. Convertible Senior Notes The carrying value of the Company’s convertible senior notes is as follows: March 31, 2018 December 31, 2017 2.125% Convertible Senior Notes due 2021: Principal amount $ 114,989 $ 115,000 Unamortized debt discount (12,513 ) (13,395 ) Unamortized debt issuance costs (2,200 ) (2,355 ) Total convertible senior notes $ 100,276 $ 99,250 On May 24, 2016, the Company issued $115 million aggregate principal amount of its Notes. The net proceeds from the sale of the Notes, after deducting the underwriting discounts and commissions and other related offering expenses, were approximately $111.1 million. The Notes bear interest at the rate of 2.125% per annum, payable semiannually in arrears on June 1 and December 1 of each year, beginning December 1, 2016. The Notes will mature on June 1, 2021, unless earlier repurchased, redeemed or converted in accordance with their terms. Prior to March 1, 2021, the Notes will be convertible at the option of holders of the Notes only upon satisfaction of certain conditions and during certain periods, and thereafter, the notes will be convertible at any time until the close of business on the second scheduled trading day immediately preceding the maturity date. Upon conversion, holders of the Notes will receive shares of the Company’s common stock, cash or a combination thereof, at the Company’s election. It is the Company’s current intent and policy to settle all conversions through combination settlement, which involves satisfying the principal amount outstanding with cash and any note conversion value over the principal amount in shares of the Company’s common stock. Notes with a par value of $11,000 were submitted for conversion in the fourth quarter of 2017, and this conversion was settled in the first quarter of 2018. The conversion resulted in the issuance of a nominal amount of shares of the Company’s common stock, and the Company recorded a loss of $1,000 on the conversion of these Notes. The Notes are not convertible as of March 31, 2018 and are classified as long term liabilities on the Company’s consolidated balance sheet as of December 31, 2017. The conversion rate for the Notes will initially be 31.1813 shares of the Company’s common stock per $1,000 principal amount of Notes, which is equivalent to an initial conversion price of approximately $32.07 per common share, and is subject to adjustment under the terms of the Notes. Holders of the Notes may require the Company to repurchase their Notes upon the occurrence of a fundamental change prior to maturity for cash at a repurchase price equal to 100% of the principal amount of the Notes to be repurchased plus accrued and unpaid interest, if any, to, but excluding, the repurchase date. The Company will not have the right to redeem the Notes prior to June 5, 2019, but may redeem the Notes, at its option, in whole or in part, on any business day on or after June 5, 2019 and prior to the maturity date if the last reported sale price of the Company’s common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which the Company provides written notice of redemption. The redemption price will be equal to 100% of the principal amount of the principal amount of Notes to be redeemed plus accrued and unpaid interest to, but excluding, the redemption date. The Notes contain customary terms and events of default. If an event of default (other than certain events of bankruptcy, insolvency or reorganization involving the Company) occurs and is continuing, the holders of at least 25% in aggregate principal amount of the outstanding Notes may declare 100% of the principal of, and any accrued and unpaid interest on, all of the Notes to be due and payable. Upon the occurrence of certain events of bankruptcy, insolvency or reorganization involving the Company, 100% of the principal of and accrued and unpaid interest, if any, on all of the Notes will become due and payable automatically. Notwithstanding the foregoing, the Notes provide that, to the extent the Company elects and for up to 270 days, the sole remedy for an event of default relating to certain failures by the Company to comply with certain reporting covenants consist exclusively of the right to receive additional interest on the Notes. The Company is not aware of any events of default, current events or market conditions that would allow holders to call or convert the Notes as of March 31, 2018. The cash conversion feature of the Notes required bifurcation from the Notes and was initially accounted for as an equity instrument classified to stockholders’ equity, as the conversion feature was determined to be clearly and closely related to the Company’s stock. Based on market data available for publicly traded, senior, unsecured corporate bonds issued by companies in the same industry and asset base and with similar maturity, the Company estimated the implied interest rate, assuming no conversion option. Assumptions used in the estimate represent what market participants would use in pricing the liability component, including market interest rates, credit standing, and yield curves, all of which are defined as Level 2 observable inputs. The estimated implied interest rate was applied to the Notes, which resulted in a fair value of the liability component of $96,289,000 upon issuance, calculated as the present value of implied future payments based on the $115 million aggregate principal amount. The equity component of the Notes was recognized as a debt discount, recorded in additional paid-in Interest expense recognized on the Notes during the three-month period ended March 31, 2018 includes $611,000, $881,000 and $155,000 for the contractual coupon interest, the accretion of the debt discount and the amortization of the debt issuance costs, respectively. The effective interest rate on the Notes is 6.6%, which includes the interest on the Notes, amortization of the debt discount and debt issuance costs. As of March 31, 2018, the carrying value of the Notes was approximately $100.3 million and the fair value of the principal was approximately $150.5 million. The fair value of the Notes was determined based on the most recent trade activity of the Notes as of March 31, 2018.

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2018
Stock-Based Compensation	11. Stock-Based Compensation For the three-month periods ended March 31, 2018 and 2017, the Company recorded stock-based compensation expense of approximately $2,268,000 and $1,531,000, respectively, for share-based awards granted under the Second Amended and Restated 2001 Repligen Corporation Stock Plan (the “2001 Plan”) and the Repligen Corporation Amended and Restated 2012 Stock Option and Incentive Plan (the “2012 Plan,” and together with the 2001 Plan, the “Plans”). The following table presents stock-based compensation expense included in the Company’s consolidated statements of comprehensive income (in thousands): Three Months Ended March 31, 2018 2017 Cost of product revenue $ 266 $ 141 Research and development 170 132 Selling, general and administrative 1,832 1,258 Total $ 2,268 $ 1,531 The 2012 Plan allows for the granting of incentive and nonqualified options to purchase shares of common stock, restricted stock and other equity awards. Employee grants under the Plans generally vest over a three- to five-year period, with 20%-33% non-employee The Company uses the Black-Scholes option pricing model to calculate the fair value of stock option awards on the grant date, and the Company uses the value of the common stock as of the grant date to value restricted stock units. The Company measures stock-based compensation cost at the grant date based on the estimated fair value of the award. The Company recognizes expense on awards with service based vesting over the employee’s requisite service period on a straight-line basis. In the third quarter of 2017, the Company issued performance stock units to certain individuals related to the Spectrum Acquisition which are tied to the achievement of certain revenue and gross margin metrics and the passage of time. The Company recognizes expense on performance based awards over the vesting period based on the probability that the performance metrics will be achieved. The Company recognizes stock-based compensation expense for options that are ultimately expected to vest, and accordingly, such compensation expense has been adjusted for estimated forfeitures. Information regarding option activity for the three-month period ended March 31, 2018 under the Plans is summarized below: Options Outstanding Weighted- Average Exercise Price Per Share Weighted- Average Remaining Contractual Term (in years) (in thousands) Aggregate Intrinsic Value Options outstanding at December 31, 2017 734,940 $ 20.80 Granted 398,532 33.85 Exercised (14,531 ) 23.70 Forfeited/cancelled (9,588 ) 29.71 Options outstanding at March 31, 2018 1,109,353 $ 25.34 7.51 $ 12,176 Options exercisable at March 31, 2018 499,504 $ 17.73 5.50 $ 9,300 Vested and expected to vest at March 31, 2018 (1) 1,057,255 $ 24.96 7.40 $ 12,015 (1) Represents the number of vested options as of March 31, 2018 plus the number of unvested options expected to vest as of March 31, 2018 based on the unvested outstanding options at March 31, 2018 adjusted for estimated forfeiture rates of 8% for awards granted to non-executive The aggregate intrinsic value in the table above represents the total pre-tax in-the-money The weighted average grant date fair value of options granted during the three-month periods ended March 31, 2018 and 2017 was $18.27 and $16.46, respectively. The total fair value of stock options that vested during the three-month periods ended March 31, 2018 and 2017 was approximately $1,339,000 and $1,195,000, respectively. Information regarding restricted stock unit and performance stock unit activity for the three-month period ended March 31, 2018 under the Plans is summarized below: Units Outstanding Weighted- Average Remaining Contractual Term (in years) (in thousands) Aggregate Intrinsic Value Restricted and performance stock units outstanding at December 31, 2017 505,235 Granted 319,701 Exercised (90,691 ) Forfeited/cancelled (31,169 ) Restricted stock units outstanding at March 31, 2018 703,076 4.06 $ 25,437 Vested and expected to vest at March 31, 2018 (1) 639,530 3.75 $ 23,138 (1) Represents the number of vested restricted stock units as of March 31, 2018 plus the number of unvested restricted stock units expected to vest as of March 31, 2018 based on the unvested outstanding restricted stock units at March 31, 2018 adjusted for estimated forfeiture rates of 8% for awards granted to non-executive The aggregate intrinsic value in the table above represents the total pre-tax The weighted average grant date fair value of restricted stock units granted during the three-month periods ended March 31, 2018 and 2017 was $33.80 and $32.18, respectively. The total grant date fair value of restricted stock units that vested during the three-month periods ended March 31, 2018 and 2017 was approximately $2,619,000 and $1,616,000, respectively. As of March 31, 2018, there was $30,762,000 of total unrecognized compensation cost related to unvested share-based awards. This cost is expected to be recognized over a weighted average remaining requisite service period of 4.66 years.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2018
Income Taxes	12. Income Taxes The Company’s effective tax rate for the three-month period ended March 31, 2018 was 24.7% compared to 24.6% for the corresponding period in the prior year. The effective tax rate for the three-month period ended March 31, 2018 was higher than the U.S. statutory tax rate of 21% due to state tax effects and the impact of the Global Intangible Low-Taxed ASU 2016-16 At December 31, 2017, the Company had net operating loss carryforwards of approximately $19,652,000 in the U.S., net operating loss carryforwards of approximately €603,000 (approximately $743,000) in Germany, federal business tax credit carryforwards of $297,000 and state business tax credit carryforwards of approximately $99,000 available to reduce future domestic income taxes, if any. The net operating loss and business tax credits carryforwards will continue to expire at various dates through December 2037. The net operating loss and business tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service. While an IRC Section 382 study was completed in the second quarter of 2017, and no current limitations were identified, use of these net operating loss and business tax credit carryforwards may be limited in the future based on certain changes in the ownership interest of significant stockholders. On December 22, 2017, the Act was signed into law. The Act made significant changes to federal tax law, including, but not limited to, a reduction in the federal income tax rate from 35% to 21%, taxation of certain global intangible low-taxed one-time The Act lowered the Company’s U.S. statutory federal tax rate from 35% to 21% effective January 1, 2018. The Company recorded a tax benefit of $12,812,000 in the year ended December 31, 2017 for the reduction in its US deferred tax assets and liabilities resulting from the rate change. The Act also includes a one-time The Company anticipates that future guidance and interpretations with the respect to the Act will cause the Company to further adjust its provisional amounts recorded as of December 31, 2017. No further adjustments have been made to these provisional amounts in the first quarter of 2018. Any measurement period adjustments will be reported as a component of provision for income taxes in the reporting period the amounts are determined. The final accounting will be completed no later than one year from the enactment of the Act. The Company’s tax returns are subject to examination by federal, state and international taxing authorities for the following periods: Jurisdiction Fiscal years subject to examination United States – federal and state 2014-2017 Sweden 2011-2017 Germany 2017 Netherlands 2012-2017

Fair Value Measurement

Fair Value Measurement	3 Months Ended
	Mar. 31, 2018
Fair Value Measurement	13. Fair Value Measurement In determining the fair value of its assets and liabilities, the Company uses various valuation approaches. The Company employs a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is broken down into three levels based on the source of inputs as follows: Level 1– Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access Level 2– Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly Level 3– Valuations based on inputs that are unobservable and significant to the overall fair value measurement The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level input that is significant to the overall fair value measurement. The Company’s fixed income investments have historically comprised of obligations of U.S. government agencies and corporate marketable securities. These investments have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third party pricing services or other market observable data. The pricing services utilize industry standard valuation models, including both income and market based approaches and observable market inputs to determine value. These observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events. At least annually, the Company validates applicable prices provided by third party pricing services by reviewing their pricing methods and matrices, obtaining market values from other pricing sources, analyzing pricing data in certain instances and confirming that the relevant markets are active. As of March 31, 2018 and December 31, 2017, the Company had no assets or liabilities for which fair value measurement is either required or has been elected to be applied. In May 2016, the Company issued $115 million aggregate principal amount of the Notes due June 1, 2021. Interest is payable semi-annually in arrears on June 1 and December 1 of each year, beginning December 1, 2016. As of March 31, 2018, the carrying value of the Notes was approximately $100.3 million, net of unamortized discount, and the fair value of the Notes was approximately $150.5 million. The fair value of the Notes was determined based on the most recent trade activity of the Notes as of March 31, 2018. These valuations are Level 1 valuations, as the valuations are based on unadjusted quoted prices in active markets that the Company has the ability to access. The Notes are discussed in more detail in Note 10, “Long Term Debt . There were no re-measurements

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2018
Commitments and Contingencies	14. Commitments and Contingencies The Company leases its headquarters in Waltham, Massachusetts as well as certain of its office and manufacturing space around the world. In February 2018, the Company entered into an agreement to lease 63,761 square feet of office and manufacturing space in Marlborough, Massachusetts from U.S. REIF 111 Locke Drive Massachusetts, LLC (the “Premises”). The lease commences during the second quarter of 2018 (the “Commencement Date”) and shall continue for a period of 126 consecutive months, unless earlier terminated in accordance with the terms of the lease (the “Lease Term”). Under the lease, the Company has the option to extend the Lease Term for two additional five-year periods. Fixed rent with respect to 40,000 square feet of the Premises only shall commence on the Commencement Date, and rent for the full 63,761 square feet of the Premises shall begin 19 months following the Commencement Date. Under the terms of the lease, the Company has provided a letter of credit of approximately $163,000 as a security deposit and is required to pay its pro rata share of any building operating expenses and real estate taxes. Future minimum rental commitments under the Company’s leases as of March 31, 2018 are as follows (in thousands): Minimum Rental 2018 (nine months remaining) $ 3,191 2019 3,808 2020 3,653 2021 3,342 2022 1,968 Thereafter 4,401

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2018
Related Party Transactions	15. Related Party Transactions Certain facilities leased by Spectrum are owned by the former owner of Spectrum, who currently holds greater than 10% of the Company’s outstanding common stock. The lease amounts paid to this shareholder were negotiated in connection with the Spectrum Acquisition. The Company has incurred rent expense totaling $201,000 for the three-month period ended March 31, 2018 related to these leases.

Segment Reporting

Segment Reporting	3 Months Ended
	Mar. 31, 2018
Segment Reporting	16. Segment Reporting The Company views its operations, makes decisions regarding how to allocate resources and manages its business as one operating segment. As a result, the financial information disclosed herein represents all of the material financial information related to the Company’s sole operating segment. The following table represents the Company’s total revenue by geographic area (based on the location of the customer): Three months ended March 31, 2018 2017 North America 45 % 38 % Europe 43 % 54 % Asia and Australia 11 % 8 % Other 1 % — Total 100 % 100 % Revenue from significant customers as a percentage of the Company’s total revenue is as follows: Three months ended March 31, 2018 2017 GE Healthcare 17 % 27 % MilliporeSigma 14 % 21 % Significant accounts receivable balances as a percentage of the Company’s total trade accounts receivable are as follows: March 31, 2018 December 31, 2017 GE Healthcare 19 % 11 % MilliporeSigma 20 % 19 %

Acquisition of Spectrum LifeS22

Acquisition of Spectrum LifeSciences, LLC (Tables) - Spectrum Inc.	3 Months Ended
	Mar. 31, 2018
Consideration Transferred	The total consideration transferred follows (in thousands): Cash consideration $ 122,932 Equity consideration 247,575 Working capital adjustment 425 Net assets acquired $ 370,932
Components and Allocation of Purchase Price	The components and allocation of the purchase price consists of the following amounts (in thousands): Cash and cash equivalents $ 10,137 Accounts receivable 5,075 Inventory 13,570 Prepaid expenses and other assets 616 Fixed assets 6,004 Deferred tax assets 1,102 Customer relationships 78,400 Developed technology 38,560 Trademark and tradename 2,160 Non-competition agreements 960 Goodwill 265,654 Accounts payable (1,335 ) Unrecognized tax benefit (576 ) Accrued liabilities (5,787 ) Deferred tax liabilities (43,608 ) Fair value of net assets acquired $ 370,932
Unaudited Supplemental Pro Forma Information	The following table presents unaudited supplemental pro forma information as if the Spectrum Acquisition had occurred as of January 1, 2017 (in thousands, except per share data): Pro-forma Three months ended March 31, 2018 Pro-forma Three months ended March 31, 2017 Total revenue 44,830 39,875 Net income 3,939 3,266 Earnings per share: Basic $ 0.09 $ 0.08 Diluted $ 0.09 $ 0.08

Revenue Recognition (Tables)

Revenue Recognition (Tables)	3 Months Ended
	Mar. 31, 2018
Disaggregation of Revenue	Revenues for the three-month periods ended March 31, 2018 and 2017 were as follows: Three months ended March 31, (in thousands, except percentages) 2018 2017 $ Change % Change Product revenue $ 44,799 $ 30,569 $ 14,230 47 % Royalty and other revenue 31 21 10 48 % Total revenue $ 44,830 $ 30,590 $ 14,240 47 %
Disaggregation of Revenue from Contracts with Customers by Geographic Region	The following tables disaggregate the Company’s revenue from contracts with customers by geographic region (in thousands). Three months ended North America $ 20,239 Europe 19,401 Asia and Pacific 4,947 Other 243 Total revenue $ 44,830
Revenue from Significant Customers	Revenue from significant customers is as follows (in thousands): Three months ended GE Healthcare $ 7,717 MilliporeSigma $ 6,465
Summary of Receivables and Deferred Revenue from Contracts with Customers	The following table provides information about receivables and deferred revenue from contracts with customers as of March 31, 2018: 2018 Balances from contracts with customers only: Accounts receivable $ 29,352 Deferred revenue 1,547 Revenue recognized in the period relating to: The beginning deferred revenue balance $ 434 Changes in pricing related to products or services satisfied in previous periods — Impairment losses on receivables —

Accumulated Other Comprehensi24

Accumulated Other Comprehensive Income (Tables)	3 Months Ended
	Mar. 31, 2018
Summary of Changes in Accumulated Other Comprehensive Income	The following table summarizes the changes in accumulated other comprehensive income by component (in thousands): (In thousands) Foreign currency translation gain (loss) Balance at December 31, 2017 $ (6,363 ) Foreign currency translation gain 251 Balance at March 31, 2018 $ (6,112 )

Earnings Per Share (Tables)

Earnings Per Share (Tables)	3 Months Ended
	Mar. 31, 2018
Basic and Diluted Weighted Average Shares Outstanding	Basic and diluted weighted average shares outstanding were as follows: Three months ended March 31, 2018 2017 Basic weighted average common shares outstanding 43,621,270 33,891,702 Effect of dilutive securities: Stock options and restricted stock awards 389,702 490,620 Convertible senior notes 315,760 — Weighted average common shares, assuming dilution 44,326,732 34,382,322

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2018
Schedule of Inventories	Inventories consist of the following (in thousands): March 31, 2018 December 31, 2017 Raw Materials $ 21,826 $ 22,351 Work-in-process 3,828 4,083 Finished products 14,470 12,570 Total $ 40,124 $ 39,004

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	3 Months Ended
	Mar. 31, 2018
Property, Plant and Equipment	Property, plant and equipment consist of the following (in thousands): March 31, 2018 December 31, 2017 Land $ 1,023 $ 1,023 Buildings 764 764 Leasehold improvements 15,740 15,673 Equipment 22,497 21,904 Furniture and fixtures 4,605 4,272 Construction in progress 3,052 2,581 Total property, plant and equipment 47,681 46,217 Less: accumulated depreciation (25,007 ) (23,800 ) Property, plant and equipment, net $ 22,674 $ 22,417

Intangible Assets (Tables)

Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2018
Intangible assets	Intangible assets consisted of the following at March 31, 2018 (in thousands): Gross Carrying Amount Accumulated Amortization Weighted Average Useful Life (in years) Technology – developed $ 51,860 $ (3,898 ) 19 Patents 240 (240 ) 8 Customer relationships 102,210 (11,446 ) 14 Trademark – definite lived 2,160 (75 ) 20 Trademark – indefinite lived 700 — — Other intangibles 1,066 (304 ) 3 Total intangible assets $ 158,236 $ (15,963 ) 16 Intangible assets consisted of the following at December 31, 2017 (in thousands): Gross Carrying Amount Accumulated Amortization Weighted Average Useful Life (in years) Technology – developed $ 51,801 $ (3,201 ) 19 Patents 240 (238 ) 8 Customer relationships 102,120 (9,636 ) 14 Trademarks – definite lived 2,160 (47 ) 20 Trademarks – indefinite lived 700 — — Other intangibles 1,063 (209 ) 3 Total intangible assets $ 158,084 $ (13,331 ) 16
Schedule of Amortization Expense for Amortized Intangible Assets	As of March 31, 2018, the Company expects to record amortization expense as follows (in thousands): Years Ending Amortization Expense December 31, 2018 (nine months remaining) $ 7,978 December 31, 2019 10,513 December 31, 2020 9,910 December 31, 2021 9,395 December 31, 2022 9,395

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2018
Accrued Liabilities	Accrued liabilities consist of the following (in thousands): March 31, 2018 December 31, 2017 Employee compensation $ 5,246 $ 9,560 Taxes 2,049 1,668 Royalty and license fees 1,243 1,383 Accrued purchases 521 1,191 Professional fees 827 947 Unearned revenue 1,547 960 Other accrued expenses 2,688 2,220 Total $ 14,121 $ 17,929

Convertible Senior Notes (Table

Convertible Senior Notes (Tables)	3 Months Ended
	Mar. 31, 2018
Carrying Value of Convertible Senior Notes	The carrying value of the Company’s convertible senior notes is as follows: March 31, 2018 December 31, 2017 2.125% Convertible Senior Notes due 2021: Principal amount $ 114,989 $ 115,000 Unamortized debt discount (12,513 ) (13,395 ) Unamortized debt issuance costs (2,200 ) (2,355 ) Total convertible senior notes $ 100,276 $ 99,250

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2018
Stock-Based Compensation Expense	The following table presents stock-based compensation expense included in the Company’s consolidated statements of comprehensive income (in thousands): Three Months Ended March 31, 2018 2017 Cost of product revenue $ 266 $ 141 Research and development 170 132 Selling, general and administrative 1,832 1,258 Total $ 2,268 $ 1,531
Summary of Option Activity	Information regarding option activity for the three-month period ended March 31, 2018 under the Plans is summarized below: Options Outstanding Weighted- Average Exercise Price Per Share Weighted- Average Remaining Contractual Term (in years) (in thousands) Aggregate Intrinsic Value Options outstanding at December 31, 2017 734,940 $ 20.80 Granted 398,532 33.85 Exercised (14,531 ) 23.70 Forfeited/cancelled (9,588 ) 29.71 Options outstanding at March 31, 2018 1,109,353 $ 25.34 7.51 $ 12,176 Options exercisable at March 31, 2018 499,504 $ 17.73 5.50 $ 9,300 Vested and expected to vest at March 31, 2018 (1) 1,057,255 $ 24.96 7.40 $ 12,015 (1) Represents the number of vested options as of March 31, 2018 plus the number of unvested options expected to vest as of March 31, 2018 based on the unvested outstanding options at March 31, 2018 adjusted for estimated forfeiture rates of 8% for awards granted to non-executive
Restricted Stock Units and Performance Stock Units
Summary of Restricted Stock Unit and Performance Stock Unit Activity	Information regarding restricted stock unit and performance stock unit activity for the three-month period ended March 31, 2018 under the Plans is summarized below: Units Outstanding Weighted- Average Remaining Contractual Term (in years) (in thousands) Aggregate Intrinsic Value Restricted and performance stock units outstanding at December 31, 2017 505,235 Granted 319,701 Exercised (90,691 ) Forfeited/cancelled (31,169 ) Restricted stock units outstanding at March 31, 2018 703,076 4.06 $ 25,437 Vested and expected to vest at March 31, 2018 (1) 639,530 3.75 $ 23,138 (1) Represents the number of vested restricted stock units as of March 31, 2018 plus the number of unvested restricted stock units expected to vest as of March 31, 2018 based on the unvested outstanding restricted stock units at March 31, 2018 adjusted for estimated forfeiture rates of 8% for awards granted to non-executive

Income Taxes (Tables)

Income Taxes (Tables)	3 Months Ended
	Mar. 31, 2018
Summary of Tax Returns Periods Subject to Examination by Federal, State and International Taxing Authorities	The Company’s tax returns are subject to examination by federal, state and international taxing authorities for the following periods: Jurisdiction Fiscal years subject to examination United States – federal and state 2014-2017 Sweden 2011-2017 Germany 2017 Netherlands 2012-2017

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2018
Future Minimum Rental Commitments under Company's Leases	Future minimum rental commitments under the Company’s leases as of March 31, 2018 are as follows (in thousands): Minimum Rental 2018 (nine months remaining) $ 3,191 2019 3,808 2020 3,653 2021 3,342 2022 1,968 Thereafter 4,401

Segment Reporting (Tables)

Segment Reporting (Tables)	3 Months Ended
	Mar. 31, 2018
Percentage of Revenue from Significant Customers	Revenue from significant customers as a percentage of the Company’s total revenue is as follows: Three months ended March 31, 2018 2017 GE Healthcare 17 % 27 % MilliporeSigma 14 % 21 %
Total Revenue
Percentage by Geographic Area or Significant Customers	The following table represents the Company’s total revenue by geographic area (based on the location of the customer): Three months ended March 31, 2018 2017 North America 45 % 38 % Europe 43 % 54 % Asia and Australia 11 % 8 % Other 1 % — Total 100 % 100 %
Accounts Receivable
Percentage by Geographic Area or Significant Customers	Significant accounts receivable balances as a percentage of the Company’s total trade accounts receivable are as follows: March 31, 2018 December 31, 2017 GE Healthcare 19 % 11 % MilliporeSigma 20 % 19 %

Basis of Presentation - Additio

Basis of Presentation - Additional Information (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
ASU No. 2016-18 | Cash, Cash Equivalents and Restricted Cash
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
New accounting pronouncement, cumulative effect of change on cash, cash equivalents and restricted cash	$ 450	$ 450

Acquisition of Spectrum LifeS36

Acquisition of Spectrum LifeSciences, LLC - Additional Information (Detail) - USD ($)	Aug. 01, 2017	Mar. 31, 2018	Dec. 31, 2017
Business Acquisition [Line Items]
Finite lived intangible asset, useful life		16 years	16 years
Goodwill		$ 327,989,000	$ 327,333,000
Customer relationships
Business Acquisition [Line Items]
Finite lived intangible asset, useful life		14 years	14 years
Technology - developed
Business Acquisition [Line Items]
Finite lived intangible asset, useful life		19 years	19 years
Spectrum Inc.
Business Acquisition [Line Items]
Cash payment to acquire business	$ 122,932,000
Shares issued for business acquisition	6,153,995
Value of common stock issued	$ 247,575,000
Working capital adjustment	425,000
Purchase price business acquisition	370,932,000
Fair value of net assets acquired	370,932,000
Goodwill	265,654,000
Goodwill expected to be deductible for tax purposes amount	0
Business acquisition, revenue		$ 11,719,000
Spectrum Inc. | Customer relationships
Business Acquisition [Line Items]
Fair value of acquired finite lived intangible assets	$ 78,400,000
Finite lived intangible asset, useful life	15 years
Spectrum Inc. | Technology - developed
Business Acquisition [Line Items]
Fair value of acquired finite lived intangible assets	$ 38,560,000
Finite lived intangible asset, useful life	20 years
Spectrum Inc. | Non-competition agreements
Business Acquisition [Line Items]
Fair value of acquired finite lived intangible assets	$ 960,000
Finite lived intangible asset, useful life	3 years
Spectrum Inc. | Trademark and Tradename
Business Acquisition [Line Items]
Fair value of acquired finite lived intangible assets	$ 2,160,000
Spectrum Inc. | Selling, general and administrative
Business Acquisition [Line Items]
Business combination, acquisition related costs		$ 655,000	$ 7,060,000

Consideration Transferred (Deta

Consideration Transferred (Detail) - Spectrum Inc. $ in Thousands	Aug. 01, 2017USD ($)
Business Acquisition [Line Items]
Cash consideration	$ 122,932
Equity consideration	247,575
Working capital adjustment	425
Total consideration transferred	$ 370,932

Components and Allocation of Pu

Components and Allocation of Purchase Price (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017	Aug. 01, 2017
Business Acquisition [Line Items]
Goodwill	$ 327,989	$ 327,333
Spectrum Inc.
Business Acquisition [Line Items]
Cash and cash equivalents			$ 10,137
Accounts receivable			5,075
Inventory			13,570
Prepaid expenses and other assets			616
Fixed assets			6,004
Deferred tax assets			1,102
Goodwill			265,654
Accounts payable			(1,335)
Unrecognized tax benefit			(576)
Accrued liabilities			(5,787)
Deferred tax liabilities			(43,608)
Net assets acquired			370,932
Spectrum Inc. | Customer relationships
Business Acquisition [Line Items]
Business combination, intangible assets			78,400
Spectrum Inc. | Technology - developed
Business Acquisition [Line Items]
Business combination, intangible assets			38,560
Spectrum Inc. | Trademark and Tradename
Business Acquisition [Line Items]
Business combination, intangible assets			2,160
Spectrum Inc. | Non-competition agreements
Business Acquisition [Line Items]
Business combination, intangible assets			$ 960

Unaudited Supplemental Pro Form

Unaudited Supplemental Pro Forma Information (Detail) - Spectrum Inc. - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Business Acquisition [Line Items]
Total revenue	$ 44,830	$ 39,875
Net income	$ 3,939	$ 3,266
Earnings per share:
Basic	$ 0.09	$ 0.08
Diluted	$ 0.09	$ 0.08

Summary of Disaggregation of Pr

Summary of Disaggregation of Product Revenues from Contracts with Customers by Major Product Line (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Disaggregation of Revenue [Line Items]
Product revenue	$ 44,799	$ 30,569
Royalty and other revenue	31	21
Total revenue	44,830	$ 30,590
Product revenue, percentage change amount	14,230
Royalty and other revenue, percentage change amount	10
Total revenue, percentage change amount	$ 14,240
Product revenue, percentage change	47.00%
Royalty and other revenue, percentage change	48.00%
Total revenue, percentage change	47.00%

Revenue from Contracts with Cus

Revenue from Contracts with Customers by Geographic Region (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Concentration Risk [Line Items]
Total revenue	$ 44,830	$ 30,590
North America
Concentration Risk [Line Items]
Total revenue	20,239
Europe
Concentration Risk [Line Items]
Total revenue	19,401
Asia and Pacific
Concentration Risk [Line Items]
Total revenue	4,947
Other
Concentration Risk [Line Items]
Total revenue	$ 243

Revenue from Significant Custom

Revenue from Significant Customers (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Concentration Risk [Line Items]
Total revenue	$ 44,830	$ 30,590
GE Healthcare
Concentration Risk [Line Items]
Total revenue	7,717
MilliporeSigma
Concentration Risk [Line Items]
Total revenue	$ 6,465

Summary of Receivables and Defe

Summary of Receivables and Deferred Revenue from Contracts with Customers (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Balances from contracts with customers only:
Accounts receivable	$ 29,352	$ 27,585
Deferred revenue	1,547
Revenue recognized in the period relating to:
The beginning deferred revenue balance	434
Changes in pricing related to products or services satisfied in previous periods	0
Impairment losses on receivables	$ 0

Change in Accumulated Other Com

Change in Accumulated Other Comprehensive Income (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	$ 591,548
Foreign currency translation gain	251	$ 1,027
Ending Balance	597,183
Foreign currency translation gain (loss)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	(6,363)
Foreign currency translation gain	251
Ending Balance	$ (6,112)

Earnings Per Share - Additional

Earnings Per Share - Additional Information (Detail) - $ / shares	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017	May 24, 2016
Computation of Earnings Per Share [Line Items]
Participating securities outstanding	0	0
Stock options, outstanding	1,109,353		734,940
Stock options, weighted average exercise price	$ 25.34		$ 20.80
Common stock excluded from calculation of diluted earnings per share	593,874	458,685
2.125% Convertible Senior Notes due 2021
Computation of Earnings Per Share [Line Items]
Notes, interest rate	2.125%			2.125%
Notes, due date	Jun. 1, 2021
Option To Purchase Common Stock
Computation of Earnings Per Share [Line Items]
Stock options, outstanding	1,109,353	805,903
Stock options, weighted average exercise price	$ 25.34	$ 19.68
Restricted Stock Units (RSUs)
Computation of Earnings Per Share [Line Items]
Common stock excluded from calculation of diluted earnings per share	703,076	404,781

Basic and Diluted Weighted Aver

Basic and Diluted Weighted Average Shares Outstanding (Detail) - shares	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Weighted Average Number of Shares Outstanding [Line Items]
Basic weighted average common shares outstanding	43,621,270	33,891,702
Effect of dilutive securities:
Stock options and restricted stock awards	389,702	490,620
Convertible senior notes	315,760
Weighted average common shares, assuming dilution	44,326,732	34,382,322

Schedule of Inventories (Detail

Schedule of Inventories (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Inventory [Line Items]
Raw materials	$ 21,826	$ 22,351
Work-in-process	3,828	4,083
Finished products	14,470	12,570
Total	$ 40,124	$ 39,004

Property, Plant and Equipment48

Property, Plant and Equipment (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Land	$ 1,023	$ 1,023
Buildings	764	764
Leasehold improvements	15,740	15,673
Equipment	22,497	21,904
Furniture and fixtures	4,605	4,272
Construction in progress	3,052	2,581
Total property, plant and equipment	47,681	46,217
Less: accumulated depreciation	(25,007)	(23,800)
Property, plant and equipment, net	$ 22,674	$ 22,417

Property, Plant and Equipment -

Property, Plant and Equipment - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Property, Plant and Equipment [Line Items]
Depreciation expense of property and equipment	$ 1,284	$ 928

Intangible Assets (Detail)

Intangible Assets (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Intangible Assets [Line Items]
Gross Carrying Amount	$ 158,236	$ 158,084
Accumulated Amortization	$ (15,963)	$ (13,331)
Weighted Average Useful Life (in years)	16 years	16 years
Trademark
Intangible Assets [Line Items]
Gross Carrying Amount, indefinite lived intangible assets	$ 700	$ 700
Technology - developed
Intangible Assets [Line Items]
Gross Carrying Amount	51,860	51,801
Accumulated Amortization	$ (3,898)	$ (3,201)
Weighted Average Useful Life (in years)	19 years	19 years
Patents
Intangible Assets [Line Items]
Gross Carrying Amount	$ 240	$ 240
Accumulated Amortization	$ (240)	$ (238)
Weighted Average Useful Life (in years)	8 years	8 years
Customer relationships
Intangible Assets [Line Items]
Gross Carrying Amount	$ 102,210	$ 102,120
Accumulated Amortization	$ (11,446)	$ (9,636)
Weighted Average Useful Life (in years)	14 years	14 years
Other intangibles
Intangible Assets [Line Items]
Gross Carrying Amount	$ 1,066	$ 1,063
Accumulated Amortization	$ (304)	$ (209)
Weighted Average Useful Life (in years)	3 years	3 years
Trademark
Intangible Assets [Line Items]
Gross Carrying Amount	$ 2,160	$ 2,160
Accumulated Amortization	$ (75)	$ (47)
Weighted Average Useful Life (in years)	20 years	20 years

Intangible Assets - Additional

Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Finite-Lived Intangible Assets [Line Items]
Amortization expense	$ 2,664	$ 715

Amortization Expense for Amorti

Amortization Expense for Amortized Intangible Assets (Detail) $ in Thousands	Mar. 31, 2018USD ($)
Finite-Lived Intangible Assets [Line Items]
Amortization Expense, December 31, 2018 (nine months remaining)	$ 7,978
Amortization Expense, December 31, 2019	10,513
Amortization Expense, December 31, 2020	9,910
Amortization Expense, December 31, 2021	9,395
Amortization Expense, December 31, 2022	$ 9,395

Schedule of Accrued Liabilities

Schedule of Accrued Liabilities (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Schedule of Accrued Liabilities [Line Items]
Employee compensation	$ 5,246	$ 9,560
Taxes	2,049	1,668
Royalty and license fees	1,243	1,383
Accrued purchases	521	1,191
Professional fees	827	947
Unearned revenue	1,547	960
Other accrued expenses	2,688	2,220
Total	$ 14,121	$ 17,929

Carrying Value of Convertible S

Carrying Value of Convertible Senior Notes (Detail) - 2.125% Convertible Senior Notes due 2021 - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Principal amount	$ 114,989	$ 115,000
Unamortized debt discount	(12,513)	(13,395)
Unamortized debt issuance costs	(2,200)	(2,355)
Total convertible senior notes	$ 100,276	$ 99,250

Carrying Value of Convertible55

Carrying Value of Convertible Senior Notes (Parenthetical) (Detail) - 2.125% Convertible Senior Notes due 2021	3 Months Ended
	Mar. 31, 2018	May 24, 2016
Debt Instrument [Line Items]
Notes, interest rate	2.125%	2.125%
Notes, due date	Jun. 1, 2021

Convertible Senior Notes - Addi

Convertible Senior Notes - Additional Information (Detail)	May 24, 2016USD ($)d$ / shares	Mar. 31, 2018USD ($)	Mar. 31, 2017USD ($)	Dec. 31, 2017USD ($)
Debt Instrument [Line Items]
Loss on conversion of senior convertible notes		$ (1,000)
Accretion of the debt discount		$ 1,036,000	$ 970,000
2.125% Convertible Senior Notes due 2021
Debt Instrument [Line Items]
Notes issued	$ 115,000,000			$ 11,000
Notes, interest rate	2.125%	2.125%
Proceeds from issuance of convertible senior notes, net of costs	$ 111,100,000
Notes, frequency of periodic payment		Semi-annually
Notes, date of first required payment		Dec. 1, 2016
Notes, due date		Jun. 1, 2021
Loss on conversion of senior convertible notes		$ (1,000)
Notes conversion ratio per $1,000 principal amount	31.1813
Notes initial conversion price | $ / shares	$ 32.07
Debt covenants debt default holder percent to declare all notes due minimum	25.00%
Number of days within which entity fails to satisfy obligations considered as event of default	270 days
Notes issued, fair value	$ 96,289,000
Contractual coupon interest		611,000
Accretion of the debt discount		881,000
Amortization of the debt issuance costs		$ 155,000
Effective interest rate on the Notes		6.60%
Notes, carrying value		$ 100,276,000		$ 99,250,000
Fair value of the note		$ 150,500,000
2.125% Convertible Senior Notes due 2021 | On any business day on or after June 5, 2019 and prior to the maturity date
Debt Instrument [Line Items]
Notes threshold percentage of stock price trigger	130.00%
Notes threshold trading days | d	20
Notes threshold consecutive trading days | d	30
Notes redemption price	100.00%

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2012	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 2,268	$ 1,531
Stock options, outstanding	1,109,353			734,940
Number of shares available for future grant	254,907
Closing price of common stock	$ 36.18
Weighted average grant date fair value of share-based awards granted	$ 18.27	$ 16.46
Total fair value of stock options vested	$ 1,339	$ 1,195
Total unrecognized compensation cost	$ 30,762
Unrecognized compensation cost, weighted average remaining requisite service period	4 years 7 months 28 days
Employee Stock Option | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incentive options, vesting period			3 years
Employee Stock Option | Minimum | Vest Over Three Year
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incentive options, vesting percentage			33.00%
Employee Stock Option | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incentive options, vesting period			5 years
Incentive options, term			10 years
Employee Stock Option | Maximum | Vest Over Five Year
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incentive options, vesting percentage			20.00%
Non-Employee Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incentive options, vesting period			1 year
Option To Purchase Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, outstanding	1,109,353	805,903
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock units, outstanding	703,076
Closing price of common stock	$ 36.18
Aggregate intrinsic value of restricted stock units vested	$ 3,224	$ 2,064
Weighted average grant date fair value of restricted stock units granted	$ 33.80	$ 32.18
Total grant date fair value of restricted stock units vested	$ 2,619	$ 1,616
Employee Stock Option and Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incentive options, vesting period	9 years

Stock-Based Compensation Expens

Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 2,268	$ 1,531
Cost of product revenue
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	266	141
Research and development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	170	132
Selling, general and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 1,832	$ 1,258

Summary of Option Activity (Det

Summary of Option Activity (Detail) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2018USD ($)$ / sharesshares
Options Outstanding
Options outstanding at December 31, 2017 | shares	734,940
Granted | shares	398,532
Exercised | shares	(14,531)
Forfeited/cancelled | shares	(9,588)
Options outstanding at March 31, 2018 | shares	1,109,353
Options exercisable at March 31, 2018 | shares	499,504
Vested and expected to vest at March 31, 2018 | shares	1,057,255	[1]
Weighted-Average Exercise Price Per Share
Options outstanding at December 31, 2017 | $ / shares	$ 20.80
Granted | $ / shares	33.85
Exercised | $ / shares	23.70
Forfeited/cancelled | $ / shares	29.71
Options outstanding at March 31, 2018 | $ / shares	25.34
Options exercisable at March 31, 2018 | $ / shares	17.73
Vested and expected to vest at March 31, 2018 | $ / shares	$ 24.96	[1]
Weighted-Average Remaining Contractual Term (in years)
Options outstanding at March 31, 2018	7 years 6 months 3 days
Options exercisable at March 31, 2018	5 years 6 months
Vested and expected to vest at March 31, 2018	7 years 4 months 24 days	[1]
Aggregate Intrinsic Value
Options outstanding at March 31, 2018 | $	$ 12,176
Options exercisable at March 31, 2018 | $	9,300
Vested and expected to vest at March 31, 2018 | $	$ 12,015	[1]
[1]	Represents the number of vested options as of March 31, 2018 plus the number of unvested options expected to vest as of March 31, 2018 based on the unvested outstanding options at March 31, 2018 adjusted for estimated forfeiture rates of 8% for awards granted to non-executive level employees and 3% for awards granted to executive level employees.

Summary of Option Activity (Par

Summary of Option Activity (Parenthetical) (Detail) - Employee Stock Option	Mar. 31, 2018
Awards Granted to Non-Executive Level Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated forfeiture rates	8.00%
Awards Granted to Executive Level Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated forfeiture rates	3.00%

Summary of Restricted Stock Uni

Summary of Restricted Stock Unit and Performance Stock Unit Activity (Detail) - Restricted Stock Units and Performance Stock Units $ in Thousands	3 Months Ended
	Mar. 31, 2018USD ($)shares
Options Outstanding
Restricted and performance stock units outstanding at December 31, 2017	505,235
Granted	319,701
Exercised	(90,691)
Forfeited/cancelled	(31,169)
Restricted stock units outstanding at March 31, 2018	703,076
Vested and expected to vest at March 31, 2018	639,530	[1]
Weighted-Average Remaining Contractual Term (in years)
Restricted stock units outstanding at March 31, 2018	4 years 22 days
Vested and expected to vest at March 31, 2018	3 years 9 months	[1]
Aggregate Intrinsic Value
Restricted stock units outstanding at March 31, 2018 | $	$ 25,437
Vested and expected to vest at March 31, 2018 | $	$ 23,138	[1]
[1]	Represents the number of vested restricted stock units as of March 31, 2018 plus the number of unvested restricted stock units expected to vest as of March 31, 2018 based on the unvested outstanding restricted stock units at March 31, 2018 adjusted for estimated forfeiture rates of 8% for awards granted to non-executive level employees and 3% for awards granted to executive level employees.

Summary of Restricted Stock U62

Summary of Restricted Stock Unit and Performance Stock Unit Activity (Parenthetical) (Detail) - Restricted Stock Units (RSUs)	Mar. 31, 2018
Awards Granted to Non-Executive Level Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated forfeiture rates	8.00%
Awards Granted to Executive Level Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated forfeiture rates	3.00%

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) € in Thousands, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017USD ($)	Jan. 01, 2018USD ($)	Dec. 31, 2017EUR (€)
Income Taxes [Line Items]
Effective tax rate	24.70%	24.60%
U.S. statutory tax rate	21.00%	34.00%	35.00%
Net operating loss carry forwards, expiration description			Expire at various dates through December 2037.
Business tax credits carry forwards, expiration description			Expire at various dates through December 2037.
Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability			$ 12,812
Tax cuts and jobs Act, increased tax provision on undistributed and previously untaxed post-1986 earnings and profits of the specified foreign corporation			3,266
Accounting Standards Update 2016-06 | Other Assets
Income Taxes [Line Items]
Impact on assets and liabilities due to change in accounting principle				$ 5,609
Accounting Standards Update 2016-06 | Deferred Tax Liabilities
Income Taxes [Line Items]
Impact on assets and liabilities due to change in accounting principle				4,932
Accounting Standards Update 2016-06 | Accumulated Deficit
Income Taxes [Line Items]
Impact on assets and liabilities due to change in accounting principle				$ 677
Domestic Tax Authority
Income Taxes [Line Items]
Business tax credits carry forwards			297
State
Income Taxes [Line Items]
Business tax credits carry forwards			99
United States
Income Taxes [Line Items]
Net operating loss carry forwards			19,652
Germany
Income Taxes [Line Items]
Net operating loss carry forwards			$ 743		€ 603

Summary of Tax Returns Periods

Summary of Tax Returns Periods Subject to Examination by Federal, State and International Taxing Authorities (Detail)	3 Months Ended
	Mar. 31, 2018
Germany
Income Tax Examination [Line Items]
Fiscal year subject to examination	2,017
Earliest Tax Year | United States
Income Tax Examination [Line Items]
Fiscal year subject to examination	2,014
Earliest Tax Year | Sweden
Income Tax Examination [Line Items]
Fiscal year subject to examination	2,011
Earliest Tax Year | Netherlands
Income Tax Examination [Line Items]
Fiscal year subject to examination	2,012
Latest Tax Year | United States
Income Tax Examination [Line Items]
Fiscal year subject to examination	2,017
Latest Tax Year | Sweden
Income Tax Examination [Line Items]
Fiscal year subject to examination	2,017
Latest Tax Year | Netherlands
Income Tax Examination [Line Items]
Fiscal year subject to examination	2,017

Fair Value Measurement - Additi

Fair Value Measurement - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2018	Dec. 31, 2017	May 24, 2016
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of other assets	$ 0	$ 0
Fair value of other liabilities	$ 0	0
2.125% Convertible Senior Notes due 2021
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Principal amount		11,000	$ 115,000,000
Notes, due date	Jun. 1, 2021
Notes, frequency of periodic payment	Semi-annually
Notes, date of first required payment	Dec. 1, 2016
Total convertible senior notes	$ 100,276,000	$ 99,250,000
Fair value of convertible senior notes	$ 150,500,000

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	Jun. 01, 2018ft²	Feb. 28, 2018ft²	Mar. 31, 2018USD ($)
Commitment And Contingencies [Line Items]
Lease agreement, space		63,761
Lease agreement, commencement date		Jun. 1, 2018
Lease agreement, term		126 months
Lease agreement, term			5 years
Number of options to extend the term			2
Lease agreement payment condition			Fixed rent with respect to 40,000 square feet of the Premises only shall commence on the Commencement Date, and rent for the full 63,761 square feet of the Premises shall begin 19 months following the Commencement Date.
Letter of Credit
Commitment And Contingencies [Line Items]
Lease agreement, security deposit | $			$ 163,000
Scenario, Forecast
Commitment And Contingencies [Line Items]
Lease agreement, space	40,000

Future Minimum Rental Commitmen

Future Minimum Rental Commitments under Company's Leases (Detail) $ in Thousands	Mar. 31, 2018USD ($)
Operating Leased Assets [Line Items]
2018 (nine months remaining)	$ 3,191
2,019	3,808
2,020	3,653
2,021	3,342
2,022	1,968
Thereafter	$ 4,401

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) (Detail) - Principal Owner $ in Thousands	3 Months Ended
	Mar. 31, 2018USD ($)
Related Party Transaction [Line Items]
Rent Expense	$ 201
Minimum
Related Party Transaction [Line Items]
Non controlling ownership interest minimum	10.00%

Percentage of Revenue by Geogra

Percentage of Revenue by Geographic Area (Detail) - Geographic Concentration Risk - Total Revenue	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Concentration Risk [Line Items]
Revenues, percentage by country	100.00%	100.00%
North America
Concentration Risk [Line Items]
Revenues, percentage by country	45.00%	38.00%
Europe
Concentration Risk [Line Items]
Revenues, percentage by country	43.00%	54.00%
Asia and Australia
Concentration Risk [Line Items]
Revenues, percentage by country	11.00%	8.00%
Other
Concentration Risk [Line Items]
Revenues, percentage by country	1.00%

Percentage of Revenue from Sign

Percentage of Revenue from Significant Customers (Detail) - Customer Concentration Risk - Sales Revenue	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
GE Healthcare
Revenue, Major Customer [Line Items]
Revenue from significant customers as a percentage of total revenue	17.00%	27.00%
MilliporeSigma
Revenue, Major Customer [Line Items]
Revenue from significant customers as a percentage of total revenue	14.00%	21.00%

Percentage of Accounts Receivab

Percentage of Accounts Receivable by Significant Customers (Detail) - Customer Concentration Risk - Accounts Receivable	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
GE Healthcare
Concentration Risk [Line Items]
Accounts receivable, percentage by customer	19.00%	11.00%
MilliporeSigma
Concentration Risk [Line Items]
Accounts receivable, percentage by customer	20.00%	19.00%